DexCom (NASDAQ:DXCM – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $65.00 to $82.00 in a research note released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the medical device company’s stock. A number of other equities research analysts also recently weighed in on DXCM. [...]